• Prime Medicine posted a net loss of $49.1 million, narrowing from $51.9 million a year earlier, while collaboration revenue fell to $856,000 from $1.45 million.
• R&D expenses dropped to $34.1 million from $40.6 million, while G&A expenses climbed to $17.4 million from $13.3 million on higher arbitration-related legal costs.
• Cash, cash equivalents, investments, and restricted cash slid to $149.2 million as of March 31, 2026, from $191.4 million at year-end 2025, with runway expected into 2027.
• Prime Medicine reiterated plans to file an IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD in mid-2026, with initial clinical data from both programs expected in 2027.
• Regulatory talks with FDA continued toward a potential BLA filing for PM359 in CGD, following positive proof-of-concept data from first two Phase 1/2 patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070800PRIMZONEFULLFEED9715021) on May 07, 2026, and is solely responsible for the information contained therein.